Characterization of Patients with Chronic Myeloid Leukemia Unresponsive to Tyrosine Kinase Inhibitors who Underwent Allogeneic Hematopoietic Stem Cell Transplantation

Characterization of Patients with Chronic Myeloid Leukemia Unresponsive to Tyrosine Kinase Inhibitors who Underwent Allogeneic Hematopoietic Stem Cell Transplantation

Background: Tyrosine kinase inhibitors (TKIs) were the first drugs to use an intracellular signaling molecule as a therapeutic target. Unresponsiveness to TKIs limits therapeutic options, making allogeneic hematopoietic stem cell transplantation (HSCT) the only option leading to molecular remission....

Full description

Bibliographic Details
Main Authors: Franceli Carvalho, Joice Zuckermann, Alessandra Paz, Gustavo Fischer, Liane Esteves Daudt, Lisandra Della Costa Rigoni, Lúcia Silla, Laura Fogliatto, Simone Martins de Castro, Diogo André Pilger
Format: Article
Language:English
Published: Tehran University of Medical Sciences 2016-12-01
Series:International Journal of Hematology-Oncology and Stem Cell Research
Subjects:
Chronic myeloid leukemia
Tyrosine kinase inhibitors
Resistance
Intolerance
Online Access:https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/585

Similar Items

Similar Items